Sign in

SILO on Nasdaq

Silo Pharma, Inc.

Silo Pharma, Inc. is an American pharmaceutical preparations company based in Sarasota.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Oncotelic Therapeutics, Inc., Benitec Biopharma Ltd or Inovio Pharmaceuticals, or pick any stock.

  • TickerSILO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSarasota, Florida1
  • Incorporated inNV2
  • Business address677 N. Washington Blvd, Sarasota, Fl 342362
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Given the global Alzheimer’s therapeutics market is projected to exceed $30.8 billion by 2033, SPC-14 presents a promising opportunity.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

38.6%Gross margin4
-5937.0%Operating margin4
-5863.5%Net margin4
0.0%Revenue growth, 20254
-67.0%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$44.3K
  • Research and development98¢$2.2M

Out of $72.1K in revenue.4 The company lost money this year.

Financial statements

Revenue5674$72.1K in 2025+78% since 2019
0$20.0K$40.0K$60.0K$80.0K2019: $40.6K$40.6K20192020: $40.9K$40.9K2020+1%2022: $72.1K$72.1K2022+76%2023: $72.1K$72.1K2023+0%2024: $72.1K$72.1K2024+0%2025: $72.1K$72.1K2025+0%
Gross profit58674$27.8K in 2025+111% since 2019
-$200.0K-$100.0K0$100.0K2019: $13.2K$13.2K20192020: -$135.2K-$135.2K20202021: $66.3K$66.3K20212022: $66.3K$66.3K2022+0%2023: $66.3K$66.3K2023+0%2024: $66.3K$66.3K2024+0%2025: $27.8K$27.8K2025−58%
Operating income598674-$4.3M in 2025+360% since 2019
-$6.0M-$4.0M-$2.0M02019: -$930.4K-$930.4K20192020: -$2.2M-$2.2M2020+137%2021: -$2.7M-$2.7M2021+25%2022: -$3.6M-$3.6M2022+32%2023: -$3.9M-$3.9M2023+6%2024: -$4.7M-$4.7M2024+22%2025: -$4.3M-$4.3M2025−9%
Net income598674-$4.2M in 2025+317% since 2019
-$5.0M-$2.5M0$2.5M$5.0M2019: -$1.0M-$1.0M20192020: -$3.0M-$3.0M2020+200%2021: $3.9M$3.9M20212022: -$3.9M-$3.9M20222023: -$3.7M-$3.7M2023−5%2024: -$4.4M-$4.4M2024+19%2025: -$4.2M-$4.2M2025−4%
Fiscal year2019202020212022202320242025
Revenue$40.6K5$40.9K5$72.1K6$72.1K7$72.1K4$72.1K4
Cost of revenue$27.4K5$176.1K5$5.0K8$5.8K6$5.8K7$5.8K4$44.3K4
Gross profit$13.2K5-$135.2K5$66.3K8$66.3K6$66.3K7$66.3K4$27.8K4
Research and development$26.2K9$693.9K8$1.3M6$845.1K7$2.4M4$2.2M4
Selling, general and admin$50.2K9$163.0K8$227.3K6$390.1K6
Operating expenses$2.8M8$3.7M6$3.9M7$4.8M4$4.3M4
Operating income-$930.4K5-$2.2M9-$2.7M8-$3.6M6-$3.9M7-$4.7M4-$4.3M4
Interest$05$809$3.0K8$2.2K6$4.9K6
Income before tax$4.2M8-$3.9M6-$3.6M7-$4.4M4-$4.2M4
Income tax$24.9K8
Net income-$1.0M5-$3.0M9$3.9M8-$3.9M6-$3.7M7-$4.4M4-$4.2M4
Earnings per share-$0.059$0.049-$1.207-$1.194-$0.504
Earnings per share (diluted)-$0.059$0.049-$1.207-$1.194-$0.504
Shares (weighted, basic)1.9M shares82.3M shares63.1M shares73.7M shares48.4M shares4
Shares (weighted, diluted)1.9M shares82.3M shares63.1M shares73.7M shares48.4M shares4

Compare Silo Pharma, Inc. with another company

Corporate structure

Silo Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Silo Pharma, Inc.

  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on Silo Pharma, Inc., latest Aug 13, 2026 (7 filings since Jun 13, 2024)
  • AdvisorShares Trust Filed SCHEDULE 13G on Silo Pharma, Inc., latest Jul 8, 2026
  • Anson Funds Management LP Filed SCHEDULE 13G/A on Silo Pharma, Inc., latest Feb 17, 2026 (2 filings since Nov 14, 2025)
  • SEG Opportunity Fund, LLC Filed SCHEDULE 13G/A on Silo Pharma, Inc., latest Feb 13, 2026 (2 filings since Oct 3, 2025)
  • RENAISSANCE TECHNOLOGIES LLC Filed SCHEDULE 13G/A on Silo Pharma, Inc., latest Feb 13, 2025 (2 filings since Nov 13, 2024)
  • Joseph Reda Filed SC 13G/A on Silo Pharma, Inc., latest Jan 25, 2024 (3 filings since Nov 16, 2022)
  • Silo Pharma, Inc. Sarasota, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Silo Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.7M4 Dec 31, 2025$3.9M4 Dec 31, 2024+21.6%
Marketable securities, current$2.1M4 Dec 31, 2025$3.2M4 Dec 31, 2024−33.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$217.4K4 Dec 31, 2025$241.2K4 Dec 31, 2024−9.9%
Finite-lived intangibles, gross$235.0K4 Dec 31, 2025$247.4K4 Dec 31, 2024−5.0%
Accumulated amortization$17.6K4 Dec 31, 2025$6.2K4 Dec 31, 2024+185.0%

Properties, in its own words

Our principal executive offices are located at 677 N. Washington Boulevard Sarasota, FL. We pay approximately $80 per month in rent for such space on a month-to-month lease basis. We believe that our current office space will be adequate for the foreseeable future.

Item 2 of the 10-K filed Mar 27, 2026.3

Leadership

Who has led Silo Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Melvin Schlossberg2013
  2. Richard Brand2014
  3. Eric Weisblum2020–now

Chair

  1. Richard Brand2014

President

  1. Melvin Schlossberg2013
  2. Eric Weisblum2014–now

Chief financial officer

  1. Donald Ptalis2013
  2. Adam C. Wasserman2016
  3. Eric Weisblum2021–2022
  4. Daniel E. Ryweck2022–now
201520202025
Board members and other officers (11)

Former names

  • Uppercut Brands, Inc.Aug 13, 2019 to Aug 14, 20202
  • Point Capital, Inc.Jan 30, 2013 to May 14, 20192
  • Gold Swap IncMar 30, 2011 to Jan 7, 20132

Timeline

  1. Oct 14, 20268-K Entered a material agreement; Unregistered sale of shares28
  2. Oct 2, 20268-K Entered a material agreement; Unregistered sale of shares29
  3. Aug 19, 20268-K Entered a material agreement; Unregistered sale of shares30
  4. Aug 17, 20268-K Bylaws or fiscal year changed; Shareholder vote31
  5. Jul 13, 20268-K Entered a material agreement; Unregistered sale of shares; Other events32
  6. Jun 18, 20268-K Other events33
  7. Jun 3, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events34
  8. Jun 1, 20268-K Other events35
  9. Apr 2, 20268-K Entered a material agreement; Unregistered sale of shares36
  10. Feb 23, 20268-K Unregistered sale of shares; Other events37
  11. Dec 29, 20258-K Listing notice or transfer38
  12. Oct 24, 20258-K Executive or director change; Shareholder vote39
  13. Apr 30, 2020New chief executive Eric Weisblum becomes CEO12
  14. Aug 1, 2014New chief executive Richard Brand becomes CEO13
  15. Jan 7, 2013New chief executive Melvin Schlossberg becomes CEO14

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202640

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

203 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 32 insider forms, 17 large holders, 3 private raises, 78 other. The latest 20:

  1. Oct 14, 20268-K CURRENT REPORT EDGAR
  2. Oct 2, 20268-K CURRENT REPORT EDGAR
  3. Aug 19, 20268-K CURRENT REPORT EDGAR
  4. Aug 17, 20268-K CURRENT REPORT EDGAR
  5. Aug 13, 202610-Q QUARTERLY REPORT EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 6, 2026EFFECT EDGAR
  8. Aug 6, 2026424B3 PROSPECTUS EDGAR
  9. Jul 31, 2026S-8 REGISTRATION STATEMENT EDGAR
  10. Jul 24, 2026S-3 REGISTRATION STATEMENT EDGAR
  11. Jul 14, 2026D EDGAR
  12. Jul 13, 20268-K CURRENT REPORT EDGAR
  13. Jul 8, 2026SCHEDULE 13G EDGAR
  14. Jun 30, 2026ARS EDGAR
  15. Jun 30, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  16. Jun 30, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  17. Jun 18, 20268-K CURRENT REPORT EDGAR
  18. Jun 18, 2026PRE 14A DEFINITIVE PROXY STATEMENT EDGAR
  19. Jun 3, 20268-K CURRENT REPORT EDGAR
  20. Jun 1, 20268-K CURRENT REPORT EDGAR

The 203 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 40 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 15, 2025Weisblum EricChief Executive OfficerBuy5,000$0.41$2.1KForm 4
Nov 21, 2025Weisblum EricChief Executive OfficerBuy1,000$0.37$370Form 4
Nov 20, 2025Weisblum EricChief Executive OfficerBuy1,000$0.37$370Form 4
Nov 19, 2025Weisblum EricChief Executive OfficerBuy4,500$0.41$1.8KForm 4
Nov 18, 2025Weisblum EricChief Executive OfficerBuy7,500$0.40$3.0KForm 4
May 27, 2025Weisblum EricChief Executive OfficerBuy10,000$0.43$4.3KForm 4
Dec 13, 2024Weisblum EricChief Executive OfficerBuy2,500$0.84$2.1KForm 4
Nov 22, 2024Weisblum EricChief Executive OfficerBuy2,500$0.90$2.2KForm 4
Nov 20, 2024Weisblum EricChief Executive OfficerBuy2,500$0.95$2.4KForm 4
Jun 12, 2024Weisblum EricChief Executive OfficerBuy4,438$1.11$4.9KForm 4
Jun 11, 2024Weisblum EricChief Executive OfficerBuy562$1.08$607Form 4
Apr 5, 2024Weisblum EricChief Executive OfficerBuy400$2.03$812Form 4
Apr 4, 2024Weisblum EricChief Executive OfficerBuy600$1.96$1.2KForm 4
Apr 1, 2024Weisblum EricChief Executive OfficerBuy1,100$1.91$2.1KForm 4
Mar 28, 2024Weisblum EricChief Executive OfficerBuy3,408$1.94$6.6KForm 4
Dec 20, 2023Weisblum EricChief Executive OfficerBuy200$1.61$322Form 4
Dec 19, 2023Weisblum EricChief Executive OfficerBuy500$1.63$815Form 4
Dec 15, 2023Weisblum EricChief Executive OfficerBuy900$1.52$1.4KForm 4
Dec 14, 2023Weisblum EricChief Executive OfficerBuy200$1.50$300Form 4
Dec 7, 2023Weisblum EricChief Executive OfficerBuy324$1.36$441Form 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Eric Weisblum,57$350.0K$521.8K47
2025Daniel Ryweck,61$60.0K$101.5K47
2024Chief Executive$350.0K$630.1K47
2024Chief Financial$60.0K$88.6K47

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 9, 2026Raised $4 million in a private offering of equity Form D: 4 investors so far Form D
  2. Jul 18, 2024Raised $2.3 million in a private offering of equity Form D: 2 investors so far Form D
  3. Jun 4, 2024Raised $2.1 million in a private offering of equity Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
AdvisorShares Investments LLC75,582$469.4K0.1%New
Citadel Advisors LLC16,800$104.3K0.0%New
Vanguard Capital Management LLC11,956$74.2K0.0%New
Vanguard Fiduciary Trust Co874$5.4K0.0%New
Tower Research Capital LLC (TRC)181$1.1K0.0%New
Harbour Investments, Inc.14$870.0%New
Citigroup Inc1$60.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Silo Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSilo Pharma, Inc.1
  • CIK0001514183
  • Employer ID (EIN)27-30463383
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address677 N. Washington Blvd, Sarasota, FL 342361
  • Phone(718) 400-90311
  • Shares outstanding1,588,250 as of Aug 13, 202611
  • Public float$5.3M as of Jun 30, 20253
  • AuditorSalberg & Company, P.A., Boca Raton, Florida PCAOB ID 106; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 30, 20111
  • Filings378 in all: 8-K (88), 10-Q (46), 4 (39), 10-K (15), CORRESP (15), 3 (14), EFFECT (13), 424B3 (11)1
    All 45 form types

    S-1/A (11), D (10), UPLOAD (10), DEF 14A (8), S-1 (8), SC 13G (8), DEFA14A (7), SCHEDULE 13G/A (7), PRE 14A (6), SC 13G/A (6), 40-17G (5), SCHEDULE 13G (5), 424B5 (4), NT 10-Q (4), 4/A (3), 8-K/A (3), ARS (3), POS AM (3), 3/A (2), 424B4 (2), DEF 14C (2), NT 10-K (2), PRE 14C (2), S-3 (2), SC 13D (2), 10-K/A (1), 8-A12B (1), 8-A12G (1), 8-K12B (1), CERT (1), D/A (1), DEFR14A (1), DRS (1), N-54A (1), N-54C (1), S-3/A (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jun 30, 2026
    Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareSILOThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Silo Pharma, Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 65 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Need for Capital
  • We have only a limited history upon which an evaluation of our prospects and future performance can be made and have no history of profitable operations.
  • We will require additional financing in the future to fund our operations.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish certain rights.
  • Risks Related to Therapeutics Businesses
  • Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our future therapeutic candidates on a timely basis or at all, which will adversely affect our business.
  • We cannot provide any assurance that any product candidates will successfully complete clinical trials or receive regulatory approval, which is necessary before they can be commercialized.
  • Any therapeutic candidates we may develop in the future may be subject to controlled substance laws and regulations in the territories where the product will be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations and our financial condition.
  • The potential reclassification of psilocybin and psilocin in the United States could create additional regulatory burdens on our operations and negatively affect our results of operations.
  • Any significant breaches in our compliance with U.S. and foreign laws and regulations governing controlled substances, or changes in the laws and regulations may result in interruptions to our development activity or business continuity.
  • The psychedelics industry and market are relatively new, and the industry may not succeed in the long term.
  • Our product candidates may contain controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current or future investigational therapies using psilocybin may negatively influence the success of these therapies.
The other 55 risks
  • Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of future product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization.
  • Even if any of our future therapeutic candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any of our future therapeutic candidates.
  • Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others.
  • The results of preclinical studies and early-stage clinical trials of our future therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.
  • We will depend on enrollment of patients in our clinical trials for our future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.
  • We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators.
  • The future commercial success of our future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large.
  • Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay.
  • We may become exposed to costly and damaging liability claims, either when testing our future therapeutic candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.
  • Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any of our future therapeutic candidates and could have a material adverse effect on our business.
  • Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.
  • Failure to comply with health and data protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.
  • The successful commercialization of any of our future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for any of our future therapeutic candidates, if approved, could limit our ability to market those therapies and decrease our ability to generate revenue.
  • We will be subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition.
  • Risks Relating to Our Intellectual Property Rights
  • The failure to obtain or maintain patents, licensing agreements and other intellectual property could materially impact our ability to compete effectively.
  • If we are unable to obtain and maintain patent protection for our products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products could be impaired.
  • We may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.
  • If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • We may spend considerable resources developing and maintaining patents, license agreements and other intellectual property that may later be abandoned or may otherwise never result in products brought to market.
  • If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.
  • We rely on information technology, and if we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations could be disrupted, and our business could be negatively affected.
  • Other Risks Related to Our Business
  • We may not be successful in hiring and retaining key employees, including executive officers.
  • Unfavorable global economic, business or political conditions could adversely affect our business, financial condition or results of operations.
  • Risks Relating to Investing in Digital Securities
  • The launch of central bank digital currencies (“CBDCs”) may adversely impact our business.
  • Absent federal regulations, there is a possibility that any digital asset we acquire may be classified as a “security.” Any classification of any digital asset we acquire as a “security” would subject us to additional regulation and could materially impact the operation of our business.
  • If we were deemed to be an investment company under the 1940 Act, applicable restrictions likely would make it impractical for us to continue segments of our business as currently contemplated.
  • We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition, and results of operations.
  • Cryptocurrency assets are less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents.
  • We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers.
  • If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to any of our acquired digital assets, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose some or all of our Solana and our financial condition and results of operations could be materially adversely affected.
  • Digital assets have historically experienced, and are expected to continue to experience, high price volatility which may influence our financial results and the market price of our common stock.
  • The availability of spot exchange traded products (ETPs) for Bitcoin and other digital assets may adversely affect the market price of our common stock.
  • A temporary or permanent blockchain “fork” to a Digital Asset blockchain network could adversely affect our business.
  • Staking introduces a risk of loss of digital assets we stake, which could adversely affect the value of our common stock.
  • Staked digital assets may be inaccessible for a variable period of time, determined by a range of factors, which could result in certain liquidity risk to the Company.
  • We have limited history in generating staking revenues from digital assets, which could adversely affect our business, financial condition and operating results.
  • Competition from other companies staking and utilizing digital assets in their treasury plans.
  • We may fail to develop and execute successful investment or trading strategies.
  • We may make, or otherwise be subject to, trade errors.
  • Risks Relating to Our Securities
  • We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their securities.
  • Our Certificate of Incorporation grants our board of directors, without any action or approval by our stockholders, the power to designate and issue preferred stock with rights, preferences and privileges that may be adverse to the rights of the holders of our common stock.
  • We have never paid cash dividends and have no plans to pay cash dividends in the future.
  • We have issued options and warrants and may continue to issue additional securities in the future. The exercise of these securities and the sale of the common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common shares.
  • Our compliance with complicated U.S. regulations concerning corporate governance and public disclosure is expensive and diverts management’s attention from our core business, which could adversely affect our business, results of operations, and financial condition.
  • Our common stock could be subject to extreme volatility.
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • We may be at risk of securities class action litigation.
  • Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.
  • Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.
  • Nasdaq Capital Market may subsequently delist our common stock if we fail to comply with ongoing listing standards.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47